Irritable Bowel Syndrome (IBS) is a gastrointestinal disorder characterized by chronic
abdominal pain and altered bowel habits in the absence of any organic cause. Patients with
IBS visit the doctor more frequently, use more diagnostic tests, consume more medications,
miss more workdays, and consume more overall direct costs than patients without IBS. More
specific treatment of the localized symptoms of IBS is therefore needed, why the present
study will investigate the effect and mechanisms of PPC-5650. PPC-5650 is a new chemical
entity that can negatively modulate the activity of Acid sensing ion channels (ASICs). It is
a potent low molecular weight inhibitor for this class of ion channels described to date.
It is hypothesized that safety, efficacy and mechanisms of local administration in the rectum
of PPC-5650 can be evaluated by use of experimental induced sensation and pain in the rectum.